Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2026-03-02 Sale | 2026-03-02 6:30 pm | Contineum Therapeutics Inc. | CTNM | Lorrain Daniel S. Chief Scientific Officer | 4,170 | $15.01 | $62,585 | 158,724 (Indirect Direct) | View |
| 2026-03-02 Sale | 2026-03-02 6:28 pm | Contineum Therapeutics Inc. | CTNM | Watkins Tim CMO & Head of Development | 3,611 | $15.02 | $54,220 | 249,167 (Direct) | View |
| 2026-02-24 Sale | 2026-02-26 4:40 pm | Contineum Therapeutics Inc. | CTNM | Stengone Carmine N. CEO and President | 7,100 | $16.02 | $113,728 | 259,488 (Direct) | View |
| 2026-02-24 Sale | 2026-02-26 4:39 pm | Contineum Therapeutics Inc. | CTNM | Lorrain Daniel S. Chief Scientific Officer | 8,124 | $16.02 | $130,164 | 301,330 (Indirect Direct) | View |
| 2026-02-19 Sale | 2026-02-20 4:05 pm | Contineum Therapeutics Inc. | CTNM | Lorrain Daniel S. Chief Scientific Officer | 100 | $16 | $1,600 | 238,324 (Indirect Direct) | View |
| 2026-02-11 Sale | 2026-02-13 4:27 pm | Contineum Therapeutics Inc. | CTNM | Stengone Carmine N. CEO and President | 400 | $16 | $6,400 | 142,971 (Direct) | View |
| 2026-02-11 Sale | 2026-02-13 4:26 pm | Contineum Therapeutics Inc. | CTNM | Lorrain Daniel S. Chief Scientific Officer | 400 | $16 | $6,400 | 238,424 (Indirect Direct) | View |
| 2026-02-03 Sale | 2026-02-05 4:24 pm | Contineum Therapeutics Inc. | CTNM | Lorrain Daniel S. Chief Scientific Officer | 4,170 | $14.94 | $62,305 | 162,894 (Indirect Direct) | View |
| 2026-01-28 Sale | 2026-01-30 4:52 pm | Contineum Therapeutics Inc. | CTNM | Watkins Tim CMO & Head of Development | 3,611 | $14.18 | $51,188 | 412,778 (Direct) | View |
| 2026-01-05 Sale | 2026-01-06 4:16 pm | Contineum Therapeutics Inc. | CTNM | Lorrain Daniel S. Chief Scientific Officer | 4,170 | $10.44 | $43,543 | 167,064 (Indirect Direct) | View |
| 2025-12-29 Sale | 2025-12-30 4:12 pm | Contineum Therapeutics Inc. | CTNM | Watkins Tim CMO & Head of Development | 3,611 | $12.06 | $43,558 | 256,389 (Direct) | View |
| 2025-12-23 Sale | 2025-12-30 4:10 pm | Contineum Therapeutics Inc. | CTNM | Lorrain Daniel S. Chief Scientific Officer | 4,170 | $12.23 | $51,009 | 171,234 (Indirect Direct) | View |
| 2024-11-25 Sale | 2024-11-27 5:06 pm | Contineum Therapeutics Inc. | CTNM | Lorrain Daniel S. Chief Scientific Officer | 1,010 | $16.02 | $16,177 | 172,460 (Indirect Direct) | View |
| 2024-11-18 Sale | 2024-11-20 5:07 pm | Contineum Therapeutics Inc. | CTNM | Lorrain Daniel S. Chief Scientific Officer | 6,190 | $16.38 | $101,421 | 173,470 (Indirect Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2026-03-02 Exercise | 2026-03-02 6:28 pm | N/A N/A | Contineum Therapeutics Inc. | CTNM | Watkins Tim CMO & Head of Development | 3,611 | $4.5 | 249,167 (Direct) | View |
| 2026-03-02 Exercise | 2026-03-02 6:28 pm | N/A 2035-04-27 | Contineum Therapeutics Inc. | CTNM | Watkins Tim CMO & Head of Development | 3,611 | $0 | 249,167 (Direct) | View |
| 2026-02-24 Exercise | 2026-02-26 4:40 pm | N/A N/A | Contineum Therapeutics Inc. | CTNM | Stengone Carmine N. CEO and President | 7,100 | $1.26 | 259,488 (Direct) | View |
| 2026-02-24 Exercise | 2026-02-26 4:40 pm | N/A 2028-11-13 | Contineum Therapeutics Inc. | CTNM | Stengone Carmine N. CEO and President | 7,100 | $0 | 259,488 (Direct) | View |
| 2026-02-24 Exercise | 2026-02-26 4:39 pm | N/A N/A | Contineum Therapeutics Inc. | CTNM | Lorrain Daniel S. Chief Scientific Officer | 8,124 | $1.01 | 301,330 (Direct) | View |
| 2026-02-24 Exercise | 2026-02-26 4:39 pm | N/A 2030-02-24 | Contineum Therapeutics Inc. | CTNM | Lorrain Daniel S. Chief Scientific Officer | 8,124 | $0 | 301,330 (Direct) | View |
| 2026-02-19 Exercise | 2026-02-20 4:05 pm | N/A N/A | Contineum Therapeutics Inc. | CTNM | Lorrain Daniel S. Chief Scientific Officer | 100 | $1.01 | 238,324 (Direct) | View |
| 2026-02-19 Exercise | 2026-02-20 4:05 pm | N/A 2030-02-24 | Contineum Therapeutics Inc. | CTNM | Lorrain Daniel S. Chief Scientific Officer | 100 | $0 | 238,324 (Direct) | View |
| 2026-02-11 Exercise | 2026-02-13 4:27 pm | N/A N/A | Contineum Therapeutics Inc. | CTNM | Stengone Carmine N. CEO and President | 400 | $1.26 | 142,971 (Direct) | View |
| 2026-02-11 Exercise | 2026-02-13 4:27 pm | N/A 2028-11-13 | Contineum Therapeutics Inc. | CTNM | Stengone Carmine N. CEO and President | 400 | $0 | 142,971 (Direct) | View |
| 2026-02-11 Exercise | 2026-02-13 4:26 pm | N/A N/A | Contineum Therapeutics Inc. | CTNM | Lorrain Daniel S. Chief Scientific Officer | 400 | $1.01 | 238,424 (Direct) | View |
| 2026-02-11 Exercise | 2026-02-13 4:26 pm | N/A 2030-02-24 | Contineum Therapeutics Inc. | CTNM | Lorrain Daniel S. Chief Scientific Officer | 400 | $0 | 238,424 (Direct) | View |
| 2026-01-30 Option Award | 2026-01-30 4:59 pm | N/A 2036-01-29 | Contineum Therapeutics Inc. | CTNM | Healy John Stephen General Counsel and Corp Sec | 206,411 | $0 | 206,411 (Direct) | View |
| 2026-01-30 Option Award | 2026-01-30 4:57 pm | N/A 2036-01-29 | Contineum Therapeutics Inc. | CTNM | Slover Peter T Chief Financial Officer | 192,000 | $0 | 192,000 (Direct) | View |
| 2026-01-30 Option Award | 2026-01-30 4:56 pm | N/A 2036-01-29 | Contineum Therapeutics Inc. | CTNM | Stengone Carmine N. CEO and President | 445,000 | $0 | 445,000 (Direct) | View |
| 2026-01-30 Option Award | 2026-01-30 4:54 pm | N/A 2036-01-29 | Contineum Therapeutics Inc. | CTNM | Lorrain Daniel S. Chief Scientific Officer | 166,500 | $0 | 166,500 (Direct) | View |
| 2026-01-28 Exercise | 2026-01-30 4:52 pm | N/A N/A | Contineum Therapeutics Inc. | CTNM | Watkins Tim CMO & Head of Development | 3,611 | $4.5 | 412,778 (Direct) | View |
| 2026-01-28 Exercise | 2026-01-30 4:52 pm | N/A 2035-04-27 | Contineum Therapeutics Inc. | CTNM | Watkins Tim CMO & Head of Development | 3,611 | $0 | 412,778 (Direct) | View |
| 2026-01-30 Option Award | 2026-01-30 4:52 pm | N/A 2036-01-29 | Contineum Therapeutics Inc. | CTNM | Watkins Tim CMO & Head of Development | 160,000 | $0 | 412,778 (Direct) | View |
| 2025-12-29 Exercise | 2025-12-30 4:12 pm | N/A N/A | Contineum Therapeutics Inc. | CTNM | Watkins Tim CMO & Head of Development | 3,611 | $4.5 | 256,389 (Direct) | View |
| 2025-12-29 Exercise | 2025-12-30 4:12 pm | N/A 2035-04-27 | Contineum Therapeutics Inc. | CTNM | Watkins Tim CMO & Head of Development | 3,611 | $0 | 256,389 (Direct) | View |
| 2025-06-26 Option Award | 2025-06-26 5:50 pm | N/A 2035-06-25 | Contineum Therapeutics Inc. | CTNM | Boyce Sarah Director | 14,750 | $0 | 14,750 (Direct) | View |
| 2025-06-26 Option Award | 2025-06-26 5:47 pm | N/A 2035-06-25 | Contineum Therapeutics Inc. | CTNM | Schimmelpennink Evert B. Director | 14,750 | $0 | 14,750 (Direct) | View |
| 2025-06-26 Option Award | 2025-06-26 5:46 pm | N/A 2035-06-25 | Contineum Therapeutics Inc. | CTNM | Brady Todd R. Director | 14,750 | $0 | 14,750 (Direct) | View |
| 2025-06-26 Option Award | 2025-06-26 5:44 pm | N/A 2035-06-25 | Contineum Therapeutics Inc. | CTNM | Ignelzi Troy A. Director | 14,750 | $0 | 14,750 (Direct) | View |
| 2025-06-26 Option Award | 2025-06-26 5:43 pm | N/A 2035-06-25 | Contineum Therapeutics Inc. | CTNM | Lyons-Williams Lori Director | 14,750 | $0 | 14,750 (Direct) | View |
| 2025-06-26 Option Award | 2025-06-26 5:41 pm | N/A 2035-06-25 | Contineum Therapeutics Inc. | CTNM | Ware Olivia C Director | 14,750 | $0 | 14,750 (Direct) | View |
| 2025-06-26 Option Award | 2025-06-26 5:39 pm | N/A 2035-06-25 | Contineum Therapeutics Inc. | CTNM | Miralles Gines Diego Director | 14,750 | $0 | 14,750 (Direct) | View |
| 2025-04-28 Option Award | 2025-04-28 4:21 pm | N/A 2035-04-27 | Contineum Therapeutics Inc. | CTNM | Watkins Tim CMO & Head of Development | 286,000 | $0 | 286,000 (Direct) | View |
| 2025-03-14 Option Award | 2025-03-17 4:12 pm | N/A 2035-03-13 | Contineum Therapeutics Inc. | CTNM | Miralles Gines Diego Director | 29,500 | $0 | 29,500 (Direct) | View |
Ownership | 2025-03-17 4:10 pm | N/A 2034-06-09 | Contineum Therapeutics Inc. | CTNM | Miralles Gines Diego Director | 0 | $0 | 5,000 (Direct) | View |
| 2025-01-31 Option Award | 2025-01-31 4:41 pm | N/A 2035-01-30 | Contineum Therapeutics Inc. | CTNM | Healy John Stephen General Counsel and Corp Sec | 63,589 | $0 | 63,589 (Direct) | View |
| 2025-01-31 Option Award | 2025-01-31 4:40 pm | N/A 2035-01-30 | Contineum Therapeutics Inc. | CTNM | Slover Peter T Chief Financial Officer | 110,000 | $0 | 110,000 (Direct) | View |
| 2025-01-31 Option Award | 2025-01-31 4:38 pm | N/A 2035-01-30 | Contineum Therapeutics Inc. | CTNM | Lorrain Daniel S. Chief Scientific Officer | 113,700 | $0 | 113,700 (Direct) | View |
| 2025-01-31 Option Award | 2025-01-31 4:38 pm | N/A 2035-01-30 | Contineum Therapeutics Inc. | CTNM | Huhn Stephen L. CMO & Sr VP, Clinical Dev. | 110,000 | $0 | 110,000 (Direct) | View |
| 2025-01-31 Option Award | 2025-01-31 4:35 pm | N/A 2035-01-30 | Contineum Therapeutics Inc. | CTNM | Stengone Carmine N. CEO and President | 300,000 | $0 | 300,000 (Direct) | View |
| 2024-08-13 Exercise | 2024-08-14 6:03 pm | N/A N/A | Contineum Therapeutics Inc. | CTNM | Huhn Stephen L. CMO & Sr VP, Clinical Dev. | 12,800 | $1.01 | 174,194 (Direct) | View |
| 2024-08-13 Exercise | 2024-08-14 6:03 pm | N/A 2030-02-24 | Contineum Therapeutics Inc. | CTNM | Huhn Stephen L. CMO & Sr VP, Clinical Dev. | 12,800 | $0 | 174,194 (Direct) | View |
| 2024-06-24 Option Award | 2024-06-24 4:25 pm | N/A 2034-06-23 | Contineum Therapeutics Inc. | CTNM | Boyce Sarah Director | 29,500 | $0 | 29,500 (Direct) | View |
| 2024-06-03 Option Award | 2024-06-03 5:46 pm | N/A 2034-06-02 | Contineum Therapeutics Inc. | CTNM | Healy John Stephen General Counsel and Corp Sec | 160,000 | $0 | 160,000 (Direct) | View |
| 2024-05-24 Option Award | 2024-05-29 5:59 pm | N/A 2034-05-23 | Contineum Therapeutics Inc. | CTNM | Stengone Carmine N. CEO and President | 285,000 | $0 | 285,000 (Direct) | View |